TME Pharma

Oncology has entered a new era with the approval of anti-cancer drugs that harness the immune system of a patient to fight back against cancer. The tumor microenvironment approach of TME Pharma to disrupt the cancer’s ability to escape the attack of the immune system is unique in the biopharmaceutical industry as it directly blocks the ability of the tumor to exploit the molecular signposts in the body used by cells on the move. The therapeutic goal is to remove the barriers or “detour” signs that cancers use to keep the immune system away.

TME Pharma is intensely focused on advancing its innovative therapeutic candidates through clinical development to demonstrate their potential to improve outcomes for cancer patients. Our compounds are designed to enhance the efficacy of both immuno-oncology approaches, such as immune checkpoint inhibitors, and other standards of care, such as chemotherapy and radiotherapy. The proprietary product candidates, based on our Spiegelmer* platform discovered and developed by TME Pharma, target the tumor microenvironment and disrupt signals used by cancer cells to deflect immune system detection and attack.

NOX-A12, our lead candidate, is in mid-stage clinical development as a combination therapy for the brain cancer, glioblastoma, where its impact on the tumor microenvironment is intended to significantly enhance the effectiveness of anti-cancer treatments without adding significant side effects for patients. TME Pharma also has clinical development plans for NOX-A12 in pancreatic cancer where it has delivered promising results. Read more here.

NOX-E36, our second clinical-stage oncology candidate, is able to target multiple tumor microenvironment chemokines that are believed to be relevant to tumor evasion of the immune system. NOX-E36 has completed exploratory clinical studies, establishing its activity on the biological targets and its safety profile. Following data suggesting potential for monotherapy efficacy in pancreatic and liver cancer pre-clinical models, TME Pharma is considering several solid tumor indications for further clinical development. Read more here.

We use cookies

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (Google Analytics cookies). You can decide for yourself whether you want to accept the cookies. Please note that if you refuse cookies, you may no longer be able to use all of the site's functions.